Exploring gefitinib to enhance endocytosis of antibodies and nucleic acid aptamers targeting EGFR in glioblastoma

Making sure you're not a bot! sciences sciences Making sure you're not a bot! Loading... You are seeing this because the administrator of this website has set up Anubis to protect the server against the scourge of AI companies aggressively scraping websites. This can and does cause downtime for the websites, which makes their resources inaccessible for everyone. Anubis is a compromise. Anubis uses a Proof-of-Work scheme in the vein of Hashcash, a proposed proof-of-work scheme for reducing email spam. The idea is that at individual scales the additional load is ignorable, but at mass scraper levels it adds up and makes scraping much more expensive. Ultimately, this is a placeholder solution so that more time can be spent on fingerprinting and identifying headless browsers (EG: via how they do font rendering) so that the challenge proof of work page doesn't need to be presented to users that are much more likely to be legitimate. Please note that Anubis requires the use of modern JavaScript features that plugins like JShelter will disable. Please disable JShelter or other such plugins for this domain. Protected by Anubis From Techaro . Mascot design by CELPHASE . This website is running Anubis version devel .

Related documents

• EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas#1008769
• Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer#910290
• Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme#842287
• Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma#902007
• Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma#859099